{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:11:47Z","timestamp":1789445507131,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.drudis.2022.103416","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T23:28:45Z","timestamp":1666394925000},"page":"103416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacological treatment strategies of pterygium: Drugs, biologics, and novel natural products"],"prefix":"10.1016","volume":"28","author":[{"given":"Sanaz Sadig","family":"Baheran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid G.","family":"Alany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sianne","family":"Schwikkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisam","family":"Muen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Namaan","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Freestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Al-Kinani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.103416_b0005","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/OPTH.S296531","article-title":"Is pterygium morphology related to loss of corneal endothelial cells? A cross-sectional study","volume":"15","author":"Zaidi","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119088","article-title":"The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved","volume":"270","author":"Zhao","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2022.103416_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mmr.2016.5223","article-title":"The role of ultraviolet radiation in the pathogenesis of pterygia","volume":"14","author":"Zhou","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2022.103416_b0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0002-9394(60)90245-2","article-title":"Pterygium: Its incidence, heredity and etiology","volume":"50","author":"Hilgers","year":"1960","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/25158414211020152","article-title":"Pterygium: an update on pathophysiology, clinical features, and management","volume":"13","author":"Shahraki","year":"2021","journal-title":"Therapeut Adv Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0030","first-page":"563","article-title":"The role of heredity in pterygium development","volume":"7","author":"Anguria","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0035","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bjo.2008.151852","article-title":"The science of pterygia","volume":"94","author":"Bradley","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.eye.6700738","article-title":"Genetic polymorphism of Hogg1 and risk of pterygium in Chinese","volume":"18","author":"Kau","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2022.103416_b0045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/bjo.77.11.734","article-title":"Pterygium as an early indicator of ultraviolet insolation: a hypothesis","volume":"77","author":"Coroneo","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2147\/OPTH.S155631","article-title":"Impact of conjunctival autograft on pterygium treatment: Evaluation of related symptoms and patients\u2019 satisfaction after surgery","volume":"12","author":"Wanzeler","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0039-6257(02)00463-0","article-title":"The treatment of pterygium","volume":"48","author":"Hirst","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0060","first-page":"1","article-title":"Molecular basis of pterygium development","author":"C\u00e1rdenas-Cant\u00fa","year":"2014","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0065","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.eye.6702064","article-title":"Increased oxidative DNA damage, 8-hydroxydeoxy- guanosine, in human pterygium","volume":"20","author":"Kau","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2022.103416_b0070","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3390\/cells10071567","article-title":"Pterygium\u2014the good, the bad, and the ugly","volume":"10","author":"Van Acker","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2022.103416_b0075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3748\/wjg.v18.i4.302","article-title":"8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases","volume":"18","author":"Ock","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2022.103416_b0080","first-page":"348","article-title":"DNA damage in human pterygium: one-shot multiple targets","volume":"19","author":"Cimpean","year":"2013","journal-title":"Mol Vision"},{"key":"10.1016\/j.drudis.2022.103416_b0085","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ajpath.2010.10.037","article-title":"Ophthalmic pterygium","volume":"178","author":"Chui","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2022.103416_b0090","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","article-title":"Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia","volume":"20","author":"Lee","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2022.103416_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/360438","article-title":"Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal","volume":"2014","author":"Ayala","year":"2014","journal-title":"Oxid Med Cell Longevity"},{"key":"10.1016\/j.drudis.2022.103416_b0105","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s10792-020-01440-2","article-title":"Role of oxidative stress and vascular endothelial growth factor expression in pterygium pathogenesis and prevention of pterygium recurrence after surgical excision","volume":"40","author":"Elgouhary","year":"2020","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40659-018-0165-8","article-title":"Extracellular matrix and fibroblast injection produces pterygium-like lesion in rabbits","volume":"51","author":"Zavala","year":"2018","journal-title":"Biol Res"},{"key":"10.1016\/j.drudis.2022.103416_b0115","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ajpath.2010.10.037","article-title":"Ophthalmic pterygium","volume":"178","author":"Chui","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2022.103416_b0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000493544","article-title":"Dry-eye disease in recurrent pterygium","volume":"61","author":"Tan","year":"2019","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.drudis.2022.103416_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1542-0124(12)70103-9","article-title":"The pathogenesis of pterygium: current concepts and their therapeutic implications","volume":"6","author":"Chui","year":"2008","journal-title":"Ocul Surf"},{"key":"10.1016\/j.drudis.2022.103416_b0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000523878","article-title":"Biomarkers in the occurrence and development of pterygium","volume":"65","author":"He","year":"2022","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.drudis.2022.103416_b0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.14748\/bro.v0i2.5068","article-title":"Surgical treatment of pterygium with conjunctival autograft","volume":"62","author":"Ilieva","year":"2018","journal-title":"Bulgarian Rev Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/8820926","article-title":"Evaluation of conjunctival autografting augmented with mitomycin C application versus Ologen implantation in the surgical treatment of recurrent pterygium","volume":"2021","author":"Wagdy","year":"2021","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0145","first-page":"22","article-title":"Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial","volume":"9","author":"Razeghinejad","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.drudis.2022.103416_b0150","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OPTH.S55259","article-title":"An update on the surgical management of pterygium and the role of loteprednol etabonate ointment","volume":"8","author":"Sheppard","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0155","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ajo.2005.12.028","article-title":"Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence","volume":"141","author":"Frucht-Pery","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0165","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0161-6420(85)33831-9","article-title":"Conjunctival autograft transplantation for advanced and recurrent pterygium","volume":"92","author":"Kenyon","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0170","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0161-6420(83)80056-6","article-title":"Conjunctival autograft transplantation for unilateral ocular surface diseases","volume":"90","author":"Herman","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0175","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICU.0b013e3281a7ecbb","article-title":"Current concepts and techniques in pterygium treatment","volume":"18","author":"Ang","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0180","first-page":"351","article-title":"Limbal epithelial autograft transplantation in treatment of pterygium","volume":"38","author":"Du","year":"1998","journal-title":"Chin J Ophth"},{"key":"10.1016\/j.drudis.2022.103416_b0185","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archopht.1997.01100160405001","article-title":"Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision","volume":"115","author":"Tan","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0190","first-page":"73","article-title":"Observation of long-term efficacy of corneal limbal conjunctival autografts in microscopy treatments of pterygium","volume":"28","author":"Yang","year":"2013","journal-title":"Eye Sci"},{"key":"10.1016\/j.drudis.2022.103416_b0195","first-page":"2825","article-title":"Conjunctival autograft in primary and recurrent pterygium: a study","volume":"7","author":"Salagar","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.drudis.2022.103416_b0200","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00417-014-2581-y","article-title":"Evaluation of the recurrence rate for pterygium treated with conjunctival autograft","volume":"252","author":"Kocamis","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ophtha.2012.06.066","article-title":"Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology","volume":"120","author":"Kaufman","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0210","first-page":"440","article-title":"Amniotic membrane transplantation in primary pterygium compared with bare sclera technique","volume":"22","author":"Arain","year":"2012","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.drudis.2022.103416_b0215","first-page":"102","article-title":"Comparison of the efficacy of pterygium resection combined with conjunctival autograft versus pterygium resection combined with amniotic membrane transplantation","volume":"27","author":"Liang","year":"2012","journal-title":"Eye Sci"},{"key":"10.1016\/j.drudis.2022.103416_b0220","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/bjo.2006.095018","article-title":"Randomised controlled study of conjunctival autograft versus amniotic membrane graft in pterygium excision","volume":"90","author":"Luanratanakorn","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0225","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/01.ico.0000116522.57227.97","article-title":"The results of amniotic membrane transplantation for primary pterygium compared with conjunctival autograft","volume":"23","author":"Tananuvat","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0230","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.eye.6700306","article-title":"Beta irradiation: new uses for an old treatment: a review","volume":"17","author":"Kirwan","year":"2003","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2022.103416_b0235","series-title":"Pterygium: Techniques and Technologies for Surgical Success","first-page":"27","article-title":"Historical approaches to pterygium surgery, including bare sclera and adjunctive beta radiation techniques","author":"Johnson","year":"2012"},{"key":"10.1016\/j.drudis.2022.103416_b0240","first-page":"228","article-title":"Isolation of new fractions of antitumor mitomycins","volume":"8","author":"Wakaki","year":"1958","journal-title":"Antibiot Chemother (Northfield)"},{"key":"10.1016\/j.drudis.2022.103416_b0245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/OPTH.S16474","article-title":"The use of mitomycin C with autologous limbal-conjunctival autograft transplantation for management of recurrent pterygium","volume":"5","author":"Fakhry","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0250","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3928\/1081-597X-20060601-08","article-title":"Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits","volume":"22","author":"Netto","year":"2006","journal-title":"J Refract Surg"},{"key":"10.1016\/j.drudis.2022.103416_b0255","first-page":"601","article-title":"Studies on pterygium. Report IV. A treatment of the pterygium by mitomycin C installation","volume":"67","author":"Kunitomo","year":"1963","journal-title":"Acta Soc Ophthalmol Jpn"},{"key":"10.1016\/j.drudis.2022.103416_b0260","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0161-6420(92)31749-X","article-title":"Serious complications of topical mitomycin-C after pterygium surgery","volume":"99","author":"Rubinfeld","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0265","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0161-6420(99)90172-0","article-title":"A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap","volume":"106","author":"Mutlu","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0275","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5301\/ejo.5000004","article-title":"Topical cyclosporine A administration after pterygium surgery","volume":"22","author":"\u00d6z\u00fclken","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0280","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0181-5512(08)74384-5","volume":"31","author":"Aydin","year":"2008","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0285","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/OPTH.S19469","article-title":"The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery","volume":"5","author":"Turan-Vural","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0290","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/OPTH.S184412","article-title":"Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease","volume":"13","author":"de Oliveira","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0295","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.drudis.2016.04.002","article-title":"Modern approaches to the ocular delivery of cyclosporine A","volume":"21","author":"Agarwal","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.103416_b0300","first-page":"e12652","article-title":"Efficacy of 5-fluorouracil in the treatment of pterygium","volume":"13","author":"Shah","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2022.103416_b0305","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","article-title":"Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa\u00ae) for dry eye disease","volume":"36","author":"Mandal","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2022.103416_b0310","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41433-019-0717-3","article-title":"Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study","volume":"34","author":"Zhai","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2022.103416_b0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/08820538.2012.730101","article-title":"Intra-operative use of 5-fluorouracil in pterygium surgery: a comparative study","volume":"28","author":"Salustiano Correa","year":"2013","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0320","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S9709","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea","volume":"4","author":"Al-Barrag","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0325","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10792-016-0358-5","article-title":"Developments and current approaches in the treatment of pterygium","volume":"37","author":"Hac\u0131o\u011flu","year":"2017","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0330","first-page":"96","article-title":"Etude comparative du Thio-tepa et de la Mitomycine C dans le traitement du pt\u00e9rygion. R\u00e9sultats pr\u00e9liminaires (A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results)","volume":"21","author":"Ngoy","year":"1998","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0335","first-page":"91","article-title":"Cyclosporine A and thiotepa in prevention of postoperative recurrence of pterygium","volume":"15","author":"Wu","year":"1999","journal-title":"Yan Ke Xue Bao"},{"key":"10.1016\/j.drudis.2022.103416_b0340","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17469899.2017.1324297","article-title":"New treatment options for pterygium","volume":"12","author":"Fuest","year":"2017","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ophtha.2012.06.066","article-title":"Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology","volume":"120","author":"Kaufman","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0350","series-title":"Eye Diseases in Hot Climates","author":"Sandford-Smith","year":"2014"},{"key":"10.1016\/j.drudis.2022.103416_b0355","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.2042-3292.2011.00343.x","article-title":"Subconjunctival drug administration in horses","volume":"24","author":"Martins","year":"2011","journal-title":"Equine Veterin Educ"},{"key":"10.1016\/j.drudis.2022.103416_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.09.016","article-title":"Vesicular systems in ocular drug delivery: an overview","volume":"269","author":"Kaur","year":"2004","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2022.103416_b0365","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1350-9462(97)00002-5","article-title":"Ophthalmic drug delivery systems\u2013recent advances","volume":"17","author":"Bourlais","year":"1998","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.drudis.2022.103416_b0370","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijpharm.2014.10.069","article-title":"Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies","volume":"477","author":"Abdelkader","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2022.103416_b0375","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2021.01.001","article-title":"The effect of a novel strategy in treating primary pterygium: a prospective randomized clinical study","volume":"225","author":"Yu","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0380","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3892\/ijmm.2013.1438","article-title":"Viral involvement in the pathogenesis and clinical features of ophthalmic pterygium (Review)","volume":"32","author":"Chalkia","year":"2013","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.drudis.2022.103416_b0385","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/ICO.0000000000001995","article-title":"Interferon alpha-2b eye drops prevent recurrence of pterygium after the bare sclera technique: a single-center, sequential, and controlled study","volume":"38","author":"Yin","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0390","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00347-009-1936-y","article-title":"Antiangiogene Therapie bei Pterygiumrezidiven (Antiangiogenic therapy for pterygium recurrence)","volume":"106","author":"Leippi","year":"2009","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.drudis.2022.103416_b0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":"Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.drudis.2022.103416_b0400","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0405","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0410","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0415","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":"Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0420","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0425","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2008.155291","article-title":"Treatment of inflamed pterygia or residual pterygial bed","volume":"93","author":"Mansour","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0435","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/ICO.0000000000001251","article-title":"Regression of inflamed pterygia by frequent high-dose intralesional ziv-aflibercept","volume":"36","author":"Mansour","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0440","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/IAE.0000000000000913","article-title":"Short- term safety profile of intravitreal ziv-aflibercept","volume":"36","author":"Chhablani","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2022.103416_b0445","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ICO.0000000000001268","article-title":"Tyrosine kinase inhibitor, vatalanib, inhibits proliferation and migration of human pterygial fibroblasts","volume":"36","author":"Kim","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2022.103416_b0450","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-015-0418-6","article-title":"Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2022.103416_b0455","doi-asserted-by":"crossref","first-page":"e0218632","DOI":"10.1371\/journal.pone.0218632","article-title":"Inhibitory effect of nintedanib on VEGF secretion in retinal pigment epithelial cells induced by exposure to a necrotic cell lysate","volume":"14","author":"Hatano","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.103416_b0460","doi-asserted-by":"crossref","first-page":"879","DOI":"10.18240\/ijo.2020.06.04","article-title":"Effect of nintedanib thermo-sensitive hydrogel on neovascularization in alkali burn rat model","volume":"13","author":"Gong","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0465","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0470","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2015.01.009","article-title":"An analysis of FDA-approved drugs: natural products and their derivatives","volume":"21","author":"Patridge","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.103416_b0475","doi-asserted-by":"crossref","first-page":"12209","DOI":"10.1021\/acs.jafc.1c04422","article-title":"Green tea catechins attenuate human primary pterygium cell survival and migration via modulation of ERK p42\/p44 and p38 pathways","volume":"69","author":"Yang","year":"2001","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.drudis.2022.103416_b0480","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/ijms17020160","article-title":"The potential of plant phenolics in prevention and therapy of skin disorders","volume":"17","author":"Dzia\u0142o","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2022.103416_b0485","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/09168451.2017.1282805","article-title":"Quercetin inhibits advanced glycation end product formation via chelating metal ions, trapping methylglyoxal, and trapping reactive oxygen species","volume":"81","author":"Bhuiyan","year":"2017","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.drudis.2022.103416_b0490","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jphp.12355","article-title":"Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens","volume":"67","author":"Abdelkader","year":"2015","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.drudis.2022.103416_b0495","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11101-014-9387-8","article-title":"Naturally occurring chalcones and their biological activities","volume":"15","author":"Rozmer","year":"2014","journal-title":"Phytochem Rev"},{"key":"10.1016\/j.drudis.2022.103416_b0500","doi-asserted-by":"crossref","first-page":"810423","DOI":"10.1155\/2013\/810423","article-title":"Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer","volume":"2013","author":"Bimonte","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2022.103416_b0505","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3892\/ijmm.2017.2944","article-title":"Efficacy of curcumin in inducing apoptosis and inhibiting the expression of VEGF in human pterygium fibroblasts","volume":"39","author":"Lu","year":"2017","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.drudis.2022.103416_b0510","doi-asserted-by":"crossref","first-page":"e99296","DOI":"10.1371\/journal.pone.0099296","article-title":"Curcumin blocks interleukin-1 signaling in chondrosarcoma cells","volume":"9","author":"Kalinski","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.103416_b0515","first-page":"3601","article-title":"Antioxidant and apoptosis-inducing activities of ellagic acid","volume":"26","author":"Han","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drudis.2022.103416_b0520","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10549-012-1977-9","article-title":"Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer","volume":"134","author":"Wang","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.drudis.2022.103416_b0525","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/molecules22081210","article-title":"Chalcone derivatives: promising starting points for drug design","volume":"22","author":"Gomes","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.103416_b0530","first-page":"1394","article-title":"Synthesis and biological evaluation of chalcone derivatives (mini review)","volume":"12","author":"Bukhari","year":"2012","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.drudis.2022.103416_b0535","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2012.06.017","article-title":"Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone","volume":"691","author":"Varinska","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2022.103416_b0540","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1248\/bpb.29.1028","article-title":"Anti-angiogenic and anti-tumor activities of 2\u2019-hydroxy-4\u2019-methoxychalcone","volume":"29","author":"Lee","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.drudis.2022.103416_b0545","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.exer.2011.02.007","article-title":"Trans-Chalcone prevents VEGF expression and retinal neovascularization in the ischemic retina","volume":"93","author":"Lamoke","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2022.103416_b0550","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00044-010-9342-1","article-title":"Synthesis, antioxidant evaluation, and quantitative structure\u2013activity relationship studies of chalcones","volume":"20","author":"Sivakumar","year":"2010","journal-title":"Med Chem Res"},{"key":"10.1016\/j.drudis.2022.103416_b0555","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10787-016-0264-5","article-title":"The antioxidant activity of some curcuminoids and chalcones","volume":"24","author":"S\u00f6kmen","year":"2016","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.drudis.2022.103416_b0560","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/molecules25051047","article-title":"Antimicrobial, antioxidant, and anticancer activities of some novel isoxazole ring containing chalcone and dihydropyrazole derivatives","volume":"25","author":"Shaik","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.103416_b0570","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/acs.jnatprod.8b00989","article-title":"The antiangiogenic activity of naturally occurring and synthetic homoisoflavonoids from the Hyacinthaceae (sensu APGII)","volume":"82","author":"Schwikkard","year":"2019","journal-title":"J Nat Prod"},{"key":"10.1016\/j.drudis.2022.103416_b0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcrs.2017.03.002","article-title":"Surgical techniques and adjuvants for the management of primary and recurrent pterygia","volume":"43","author":"Hovanesian","year":"2017","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.drudis.2022.103416_b0270","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bjophthalmol-2017-310288","article-title":"Comparison among adjuvant treatments for primary pterygium: a network meta-analysis","volume":"102","author":"Fonseca","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.103416_b0430","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2005.01.023","article-title":"Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia","volume":"112","author":"Gebhardt","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2022.103416_b0565","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2011.12.012","article-title":"The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases","volume":"677","author":"Lee","year":"2012","journal-title":"Eur J Pharmacol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:06:27Z","timestamp":1761224787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622004093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1359644622004093"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103416","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment strategies of pterygium: Drugs, biologics, and novel natural products","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103416"}}